Amgen: I Prefer To Chase Value And Dividends

Vertigo3d Anybody who's invested in the pharmaceutical space knows that industry giants like Pfizer (PFE) and Gilead Sciences (GILD) are subject to boom and bust cycles as it relates to patent cliffs and new drug development. That's why capital allocation is so important to sustaining shareholder returns, and those who can do it well tend to outperform peers and even the market itself. This brings me to Amgen (NASDAQ:AMGN), which has done well for shareholders over its history. I last covered the stock back ...